Alejandro López-Neyra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandro López-Neyra has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Cristina de Manuel Gómez
Paediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitario La Paz Institute for Health Research – IdiPAZ, Madrid, Spain
7 shared publications - Verónica Sanz-Santiago
Department of Paediatric Pulmonology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
6 shared publications - Andrea Freixa
Department of Pediatrics, Obstetrics and Gynecology and Preventive Medicine and Public Health, University Autònoma de Barcelona, Bellaterra, Spain; Pediatric Cardiology Service, Vall Hebron University Hospital, Barcelona, Spain; Pediatric Cardiology Service, Royal Brompton Hospital, London, United Kingdom
4 shared publications - Margarita Pérez
ImFINE Research Group, Department of Health and Human Performance, Universidad Politécnica de Madrid, Madrid, Spain
4 shared publications - Miguel Tortajada-Girbés
Hospital Universitario y Politécnico La Fe Valencia Spain
4 shared publications - Teresa Garriga-Baraut
Hospital Universitario Vall d’Hebron, 08035 Barcelona, Spain
4 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2600265
Home-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial
Introduction: While high-intensity interval training (HIIT) has shown effectiveness in improving cardiorespiratory fitness (CRF) across various chronic respiratory diseases, its impacts on individuals with post-infectious bronchiolitis obliterans (PIBO) remain unexplored. Aim: To assess the effects of a home-based remotely-supervised HIIT programme on CRF, clinical and functional variables in patients with PIBO. Methods: Participants of this assessor-blinded, multicentre, randomized controlled trial were individuals with PIBO aged 6 to 20 years. An exercise group (EXE) underwent two 40-min sessions of HIIT remotely supervised in real time per week. Sessions were continued for 16 weeks. The control group (CON) adhered to general physical activity recommendations. The primary outcome was peak oxygen consumption (VO 2 peak), time to ventilatory threshold (VT 1 ), percentage of VO 2 at VT 1 , and ventilatory equivalent for carbon dioxide, determined via cardiopulmonary exercise testing on a treadmill. Secondary outcomes were lung function (spirometry), muscle strength (dynamometry), functional capacity (30-second Sit-To-Stand test), body mass index, and Saint George Respiratory Questionnaire. Results: Fifty-one PIBO patients were enrolled (EXE=25; CON=26) (mean age 13.3±4.2 years; females 49%; FEV 1 −3.56±1.28 (z-score); VO 2 peak 36.8±8.6 mL.kg −1 .min −1 ). The HIIT intervention resulted in improvements in VO 2 peak (Δ=3.39; p=0.04), time (min) to VT 1 (Δ=1.05; p=0.04), and in the number of repetitions in the 30s-STS (Δ=2.21; p=0.04). No differences were found in the other variables. Conclusions: Our real-time, remotely-supervised HIIT intervention was effective at significantly increasing CRF and functional capacity in children and adolescents with PIBO.
- 4 June 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2600265
Open AccessHome-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial
Introduction: While high-intensity interval training (HIIT) has shown effectiveness in improving cardiorespiratory fitness (CRF) across various chronic respiratory diseases, its impacts on individuals with post-infectious bronchiolitis obliterans (PIBO) remain unexplored. Aim: To assess the effects of a home-based remotely-supervised HIIT programme on CRF, clinical and functional variables in patients with PIBO. Methods: Participants of this assessor-blinded, multicentre, randomized controlled trial were individuals with PIBO aged 6 to 20 years. An exercise group (EXE) underwent two 40-min sessions of HIIT remotely supervised in real time per week. Sessions were continued for 16 weeks. The control group (CON) adhered to general physical activity recommendations. The primary outcome was peak oxygen consumption (VO 2 peak), time to ventilatory threshold (VT 1 ), percentage of VO 2 at VT 1 , and ventilatory equivalent for carbon dioxide, determined via cardiopulmonary exercise testing on a treadmill. Secondary outcomes were lung function (spirometry), muscle strength (dynamometry), functional capacity (30-second Sit-To-Stand test), body mass index, and Saint George Respiratory Questionnaire. Results: Fifty-one PIBO patients were enrolled (EXE=25; CON=26) (mean age 13.3±4.2 years; females 49%; FEV 1 −3.56±1.28 (z-score); VO 2 peak 36.8±8.6 mL.kg −1 .min −1 ). The HIIT intervention resulted in improvements in VO 2 peak (Δ=3.39; p=0.04), time (min) to VT 1 (Δ=1.05; p=0.04), and in the number of repetitions in the 30s-STS (Δ=2.21; p=0.04). No differences were found in the other variables. Conclusions: Our real-time, remotely-supervised HIIT intervention was effective at significantly increasing CRF and functional capacity in children and adolescents with PIBO.
- Open Access
- 18 September 2025
- Published by Wiley in Current Protocols
- Vol. 5 (9) , e70202
Strength‐Oriented Virtual Exercise Training Intervention in Children and Adolescents with Cystic Fibrosis Under CFTR Modulators (the FIQMODE Study): Study Protocol for a Randomized Controlled Trial
Muscle health has not been thoroughly analyzed in pediatric cystic fibrosis (CF) under elexacaftor/tezacaftor/ivacaftor (ETI) therapy together with exercise interventions in randomized controlled trials (RCTs). The aim of this study will be to determine the effects of a virtual live exercise training intervention on muscle health and cardiorespiratory fitness (CRF) variables in a pediatric population with CF under ETI therapy. The ‘FIQMODE’ Study (FIQ for CF in Spanish, or fibrosis quística; MOD for modulator therapy; and E for exercise) is a two‐arm RCT to evaluate the feasibility and efficacy of a novel exercise intervention to improve the muscle health and quality of life (QoL) of children and adolescents with CF under ETI pharmacological therapies. The exercise group will follow a 16‐week, supervised, strength‐oriented virtual live exercise training intervention. The control group will follow the standard World Health Organization recommendations for physical activity. Primary outcomes will be muscle health (lower and upper limb strength, respiratory muscle strength, lower limb functional mobility, anthropometry, and body composition) and CRF. Secondary outcomes will be clinical history, lung function, inflammatory status, lifestyle and QoL, adherence, and the Mediterranean Diet Quality Index. Participants will complete measures at baseline (pre‐intervention), 16 weeks post‐intervention, and 8 months follow‐up after the intervention. FIQMODE will provide an evidence‐informed protocol for exercise‐based therapy focused on outcomes reported in a robust RCT that can be applied across children and adolescents with CF under ETI therapy. FIQMODE will support the standardization of CF therapies with ETI together with exercise therapies, which will maximize the usability of exercise in medical applications, improve muscle quality, reduce pulmonary exacerbation, boost pharmacological improvement, and ultimately help improve the lifestyle of children and adolescents with CF.Trial registration: The protocol has been approved by the Ethics Committee of the Universidad Politécnica de Madrid (REF. 20231215) and registered on ClinicalTrials.gov (NCT06322446). This research was funded by the Instituto de Salud Carlos III, which is co‐funded by the European Regional Development Fund (PI 23/00299). The Instituto de Salud Carlos III supported this study through the project agreement “FIQMODE” with the Universidad Politécnica de Madrid (C2311600157). © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC.
- 18 September 2025
- Published by Wiley in Current Protocols
- Vol. 5 (9) , e70202
Open AccessStrength‐Oriented Virtual Exercise Training Intervention in Children and Adolescents with Cystic Fibrosis Under CFTR Modulators (the FIQMODE Study): Study Protocol for a Randomized Controlled Trial
Muscle health has not been thoroughly analyzed in pediatric cystic fibrosis (CF) under elexacaftor/tezacaftor/ivacaftor (ETI) therapy together with exercise interventions in randomized controlled trials (RCTs). The aim of this study will be to determine the effects of a virtual live exercise training intervention on muscle health and cardiorespiratory fitness (CRF) variables in a pediatric population with CF under ETI therapy. The ‘FIQMODE’ Study (FIQ for CF in Spanish, or fibrosis quística; MOD for modulator therapy; and E for exercise) is a two‐arm RCT to evaluate the feasibility and efficacy of a novel exercise intervention to improve the muscle health and quality of life (QoL) of children and adolescents with CF under ETI pharmacological therapies. The exercise group will follow a 16‐week, supervised, strength‐oriented virtual live exercise training intervention. The control group will follow the standard World Health Organization recommendations for physical activity. Primary outcomes will be muscle health (lower and upper limb strength, respiratory muscle strength, lower limb functional mobility, anthropometry, and body composition) and CRF. Secondary outcomes will be clinical history, lung function, inflammatory status, lifestyle and QoL, adherence, and the Mediterranean Diet Quality Index. Participants will complete measures at baseline (pre‐intervention), 16 weeks post‐intervention, and 8 months follow‐up after the intervention. FIQMODE will provide an evidence‐informed protocol for exercise‐based therapy focused on outcomes reported in a robust RCT that can be applied across children and adolescents with CF under ETI therapy. FIQMODE will support the standardization of CF therapies with ETI together with exercise therapies, which will maximize the usability of exercise in medical applications, improve muscle quality, reduce pulmonary exacerbation, boost pharmacological improvement, and ultimately help improve the lifestyle of children and adolescents with CF.Trial registration: The protocol has been approved by the Ethics Committee of the Universidad Politécnica de Madrid (REF. 20231215) and registered on ClinicalTrials.gov (NCT06322446). This research was funded by the Instituto de Salud Carlos III, which is co‐funded by the European Regional Development Fund (PI 23/00299). The Instituto de Salud Carlos III supported this study through the project agreement “FIQMODE” with the Universidad Politécnica de Madrid (C2311600157). © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC.
- Open Access
- 17 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Cardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study
Background: Post-infectious bronchiolitis obliterans (PIBO) arises after lower respiratory tract infection during childhood and is marked by impaired lung function. Despite possible impacts on exercise capacity, cardiorespiratory fitness in PIBO patients remain largely unknown. This study aimed to examine cardiorespiratory fitness and identify possible demographic and clinical–functional associations. Methods: The following variables were examined in a multicentre, cross-sectional study conducted in clinically stable PIBO patients aged 6–20 years: cardiorespiratory fitness (exercise testing), lung function (spirometry and impulse oscillometry), muscle strength (handgrip, upper and lower extremities), functional capacity (30-s sit-to-stand (STS) test), physical activity level (physical activity questionnaire adolescents and children; PAQ-A-C), body mass index (BMI), quality of life (Saint George's respiratory questionnaire; SGRQ) and dyspnoea perception (modified Medical Research Council scale). Results: 51 patients were enrolled (mean age 13.2±4.2 years, 49% female). BMI z-score was 0.06±1.20. Lung function tests indicated moderate-to-severe obstruction (forced expiratory volume in 1 s (FEV 1 ) z-score −3.55±1.30) and elevated airway resistance (R5 Hz 165.8±53.64%). Peak oxygen consumption ( V′ O 2 peak ) was 36.8±8.58 mL·kg −1 ·min −1 (47% ≤10 percentile) and breathing reserve 7.08±8.29%, indicating ventilatory limitation. Handgrip strength was 0.49±0.14 kg·kg −1 . The 30-s STS test was 27.2±5.7 repetitions. PAQ-A/PAQ-C was 1.89±0.46 indicating a low physical activity level. SGRQ was 20.1±10.8%. There was no resting dyspnoea. Multivariate regression identified significant associations between V′ O 2 peak and FEV 1 (p<0.001), BMI (p<0.001), SGRQ (p=0.005), female sex (p=0.002) and age (p=0.033). Conclusions: In these patients, cardiorespiratory fitness was impaired mainly due to ventilatory limitations. Lung function, upper and lower limb muscle strength, BMI, quality of life, sex and age were all associated with fitness level.
- 17 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessCardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study
Background: Post-infectious bronchiolitis obliterans (PIBO) arises after lower respiratory tract infection during childhood and is marked by impaired lung function. Despite possible impacts on exercise capacity, cardiorespiratory fitness in PIBO patients remain largely unknown. This study aimed to examine cardiorespiratory fitness and identify possible demographic and clinical–functional associations. Methods: The following variables were examined in a multicentre, cross-sectional study conducted in clinically stable PIBO patients aged 6–20 years: cardiorespiratory fitness (exercise testing), lung function (spirometry and impulse oscillometry), muscle strength (handgrip, upper and lower extremities), functional capacity (30-s sit-to-stand (STS) test), physical activity level (physical activity questionnaire adolescents and children; PAQ-A-C), body mass index (BMI), quality of life (Saint George's respiratory questionnaire; SGRQ) and dyspnoea perception (modified Medical Research Council scale). Results: 51 patients were enrolled (mean age 13.2±4.2 years, 49% female). BMI z-score was 0.06±1.20. Lung function tests indicated moderate-to-severe obstruction (forced expiratory volume in 1 s (FEV 1 ) z-score −3.55±1.30) and elevated airway resistance (R5 Hz 165.8±53.64%). Peak oxygen consumption ( V′ O 2 peak ) was 36.8±8.58 mL·kg −1 ·min −1 (47% ≤10 percentile) and breathing reserve 7.08±8.29%, indicating ventilatory limitation. Handgrip strength was 0.49±0.14 kg·kg −1 . The 30-s STS test was 27.2±5.7 repetitions. PAQ-A/PAQ-C was 1.89±0.46 indicating a low physical activity level. SGRQ was 20.1±10.8%. There was no resting dyspnoea. Multivariate regression identified significant associations between V′ O 2 peak and FEV 1 (p<0.001), BMI (p<0.001), SGRQ (p=0.005), female sex (p=0.002) and age (p=0.033). Conclusions: In these patients, cardiorespiratory fitness was impaired mainly due to ventilatory limitations. Lung function, upper and lower limb muscle strength, BMI, quality of life, sex and age were all associated with fitness level.
- Open Access
Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies
Objective: The objective of this study was to analyze respiratory muscle function in children and adolescents with cystic fibrosis (CF) treated with Elexacaftor/Tezacaftor/Ivacaftor (ETI) compared to healthy individuals, based on the hypothesis that CFTR modulators may improve respiratory muscle strength. Methods: A descriptive, observational, cross-sectional study was conducted with patients with CF treated with ETI aged 6–18 years. Lung function, maximal expiratory and inspiratory pressures (MIP and MEP), diet quality (KIDMED), and physical activity levels (PAQ) were assessed. The student’s t-test or the Mann–Whitney U-test was used to compare differences between groups. The effect size was calculated with Cohen’s d. Significance level was set as a p-value < 0.05. Results: A total of 48 children and adolescents (60.4% male) were analyzed in this study (24 healthy and 24 with CF). The participants with CF had mild pulmonary involvement. No significant differences were found in respiratory muscle strength between groups (MEPmax p = 0.440, MIPmax p = 0.206). Patients with CF showed lower KIDMED (p = 0.022) and PAQ (p = 0.010) scores. However, the MIP and MEP values observed in CF participants were higher than those reported in previous studies conducted before the introduction of ETI modulators. Conclusions: Children and adolescents with CF treated with ETI showed respiratory muscle strength comparable to that of healthy controls. Despite differences in lifestyle factors, these findings may reflect a positive impact of CFTR modulators on respiratory muscle function, although further longitudinal and controlled studies are needed.
Open AccessRespiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies
Objective: The objective of this study was to analyze respiratory muscle function in children and adolescents with cystic fibrosis (CF) treated with Elexacaftor/Tezacaftor/Ivacaftor (ETI) compared to healthy individuals, based on the hypothesis that CFTR modulators may improve respiratory muscle strength. Methods: A descriptive, observational, cross-sectional study was conducted with patients with CF treated with ETI aged 6–18 years. Lung function, maximal expiratory and inspiratory pressures (MIP and MEP), diet quality (KIDMED), and physical activity levels (PAQ) were assessed. The student’s t-test or the Mann–Whitney U-test was used to compare differences between groups. The effect size was calculated with Cohen’s d. Significance level was set as a p-value < 0.05. Results: A total of 48 children and adolescents (60.4% male) were analyzed in this study (24 healthy and 24 with CF). The participants with CF had mild pulmonary involvement. No significant differences were found in respiratory muscle strength between groups (MEPmax p = 0.440, MIPmax p = 0.206). Patients with CF showed lower KIDMED (p = 0.022) and PAQ (p = 0.010) scores. However, the MIP and MEP values observed in CF participants were higher than those reported in previous studies conducted before the introduction of ETI modulators. Conclusions: Children and adolescents with CF treated with ETI showed respiratory muscle strength comparable to that of healthy controls. Despite differences in lifestyle factors, these findings may reflect a positive impact of CFTR modulators on respiratory muscle function, although further longitudinal and controlled studies are needed.
- Open Access
- 17 August 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (11) , 3195-3205
SARS‐CoV‐2 infection in children with cystic fibrosis: A cross‐sectional multicenter study in Spain. New waves, new knowledge
Introduction: The association between viral infections and pulmonary exacerbations in children with cystic fibrosis (cwCF) is well established. However, the question of whether cwCF are at a higher risk of COVID‐19 or its adverse consequences remains controversial.Methods: We conducted an observational, multicenter, cross‐sectional study of cwCF infected by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) between March 2020 and June 2022, (first to sixth COVID‐19 pandemic waves) in Spain. The study aimed to describe patients' basal characteristics, SARS‐CoV‐2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves.Results: During study time, 351 SARS‐CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0–17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (sixth wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid‐19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). Infection occurring along the sixth wave was the only independent risk factor for being symptomatic. Just eight cwCF needed hospital admission. No multisystem inflammatory syndrome, persisting symptoms, long‐term sequelae, or deaths were reported.Conclusions: Spanish current data indicate that cwCF do not experience higher risks of SARS‐CoV‐2 infection nor worse health outcomes or sequelae. Changes in patients' basal characteristics, clinical courses, and outcomes were detected across waves. While the pandemic continues, a worldwide monitoring of COVID‐19 in pediatric CF patients is needed.
- 17 August 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (11) , 3195-3205
Open AccessSARS‐CoV‐2 infection in children with cystic fibrosis: A cross‐sectional multicenter study in Spain. New waves, new knowledge
Introduction: The association between viral infections and pulmonary exacerbations in children with cystic fibrosis (cwCF) is well established. However, the question of whether cwCF are at a higher risk of COVID‐19 or its adverse consequences remains controversial.Methods: We conducted an observational, multicenter, cross‐sectional study of cwCF infected by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) between March 2020 and June 2022, (first to sixth COVID‐19 pandemic waves) in Spain. The study aimed to describe patients' basal characteristics, SARS‐CoV‐2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves.Results: During study time, 351 SARS‐CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0–17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (sixth wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid‐19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). Infection occurring along the sixth wave was the only independent risk factor for being symptomatic. Just eight cwCF needed hospital admission. No multisystem inflammatory syndrome, persisting symptoms, long‐term sequelae, or deaths were reported.Conclusions: Spanish current data indicate that cwCF do not experience higher risks of SARS‐CoV‐2 infection nor worse health outcomes or sequelae. Changes in patients' basal characteristics, clinical courses, and outcomes were detected across waves. While the pandemic continues, a worldwide monitoring of COVID‐19 in pediatric CF patients is needed.
- Open Access
- 11 April 2023
- Published by Wiley
SARS-CoV-2 infection in children with Cystic Fibrosis: A Cross-sectional Multicenter Study in Spain. New waves, new knowledge.
Introduction Viral infections are associated with pulmonary exacerbations in children with Cystic Fibrosis (cwCF), but after 3 years of SARS-CoV-2 pandemic, whether cwCF are at higher risk of developing COVID-19 or its adverse consequences remains controversial. Methods We conducted an observational, multicenter, cross-sectional study of cwCF infected by SARS-CoV-2 between March 2020 and June 2022, (1 st to 6 th COVID-19 pandemic waves) in Spain. The study aimed to describe patients’ basal characteristics, SARS-CoV-2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves. Results During study time, 351 SARS-CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0-17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (6 th wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid-19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). No multisystem inflammatory syndrome (MIS-C), persisting symptoms, long-term sequelae or deaths were reported. Conclusions Spanish current data indicate that cwCF do not experience higher risks of SARS-CoV-2 infection nor worse health outcomes or sequelae. Changes in patients’ basal characteristics, clinical courses and outcomes were detected across waves. While the pandemic continues, and new SARS-CoV-2 variants are being identified, a worldwide monitoring of COVID-19 in pediatric CF patients is needed.
- 11 April 2023
- Published by Wiley
Open AccessSARS-CoV-2 infection in children with Cystic Fibrosis: A Cross-sectional Multicenter Study in Spain. New waves, new knowledge.
Introduction Viral infections are associated with pulmonary exacerbations in children with Cystic Fibrosis (cwCF), but after 3 years of SARS-CoV-2 pandemic, whether cwCF are at higher risk of developing COVID-19 or its adverse consequences remains controversial. Methods We conducted an observational, multicenter, cross-sectional study of cwCF infected by SARS-CoV-2 between March 2020 and June 2022, (1 st to 6 th COVID-19 pandemic waves) in Spain. The study aimed to describe patients’ basal characteristics, SARS-CoV-2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves. Results During study time, 351 SARS-CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0-17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (6 th wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid-19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). No multisystem inflammatory syndrome (MIS-C), persisting symptoms, long-term sequelae or deaths were reported. Conclusions Spanish current data indicate that cwCF do not experience higher risks of SARS-CoV-2 infection nor worse health outcomes or sequelae. Changes in patients’ basal characteristics, clinical courses and outcomes were detected across waves. While the pandemic continues, and new SARS-CoV-2 variants are being identified, a worldwide monitoring of COVID-19 in pediatric CF patients is needed.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- Open Access
- 24 January 2023
- Published by Wiley
COST-EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF SEVERE PEDIATRIC ALLERGIC ASTHMA- RESULTS OF A REAL-LIFE STUDY IN SPAIN
BACKGROUND Severe Pediatric Allergic Asthma (SPAA) induces a huge economic burden in terms of direct, indirect and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective. METHODS A sample of 426 children with SPAA from the ANCHORS study was used to calculate the Incremental Cost Effectiveness Ratio (ICER) for the avoidance of Moderate to Severe Exacerbations (MSE), and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data of health encounters and drug consumption before and up to six years after the beginning of the treatment with omalizumab. RESULTS The ICER per avoided MSE was \euro2,107 after one year, and it consistently decreased to \euro656 in those followed up to six years. Similarly, the ICER for the Minimally Important Difference in control tests showed a decrease from \euro2,059 to \euro380 per each 0.5 points of improvement in ACQ5, and from \euro3,141 to \euro2,322 per each 3 points improvement in c-ACT, at years 1 and 6 respectively. CONCLUSION The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, mainly those who have frequent exacerbations, showing progressively reduced costs in successive years of treatment.
- 24 January 2023
- Published by Wiley
Open AccessCOST-EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF SEVERE PEDIATRIC ALLERGIC ASTHMA- RESULTS OF A REAL-LIFE STUDY IN SPAIN
BACKGROUND Severe Pediatric Allergic Asthma (SPAA) induces a huge economic burden in terms of direct, indirect and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective. METHODS A sample of 426 children with SPAA from the ANCHORS study was used to calculate the Incremental Cost Effectiveness Ratio (ICER) for the avoidance of Moderate to Severe Exacerbations (MSE), and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data of health encounters and drug consumption before and up to six years after the beginning of the treatment with omalizumab. RESULTS The ICER per avoided MSE was \euro2,107 after one year, and it consistently decreased to \euro656 in those followed up to six years. Similarly, the ICER for the Minimally Important Difference in control tests showed a decrease from \euro2,059 to \euro380 per each 0.5 points of improvement in ACQ5, and from \euro3,141 to \euro2,322 per each 3 points improvement in c-ACT, at years 1 and 6 respectively. CONCLUSION The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, mainly those who have frequent exacerbations, showing progressively reduced costs in successive years of treatment.
- Open Access
- 11 January 2023
- Published by Wiley
“Soluble form of the receptor for advanced glycation end products (sRAGE) as a marker of inflammation in pediatric cystic fibrosis population, a pilot study.”
The receptor for advanced glycation end products (RAGE) has been studied in several respiratory diseases described as an important inflammatory mediator. The RAGE-axis is activated by multiple endogenous ligands related to pro-inflammatory states, upregulate the RAGE expression. The function of soluble RAGE (sRAGE) is not completely understood, it has been hypothesized an anti-inflamatory role as RAGE decoy receptor. Few studies have explored the RAGE-axis in Cystic Fibrosis (CF) with contradictory results. Based on previously, we present this pilot study with the aim of describe the plasma sRAGE levels in children with cystic CF (CFp), compare with the sRAGE levels in a healthy cohort and study its possible correlation with CFp clinical features. We conducted a single-center, cross-sectional observational study. We included 35 clinically stable CF patients (aged < 18 years). The median plasma sRAGE level in CFp was 1494,75 pg/ml [interquartile range (IQR) 708,75pg/ml], compared with 714,20 pg/ml (IQR 490,50 pg/ml)) in the historical cohort of healthy controls (p < 0,001). A positive correlation was found between plasma sRAGE level and forced expiratory volume in 1 second/forced vital capacity ratio (FEV1/FVC) (p 0,004) and forced expiratory flow between 25% and 75% (FEF25%-75%) (p 0,032). In this preliminary study, the plasma sRAGE level were higher in CFp than in healthy controls. Also, we described a positive correlation between FEV1/FVC and FEF25%-75% and plasma sRAGE. To our knowledge, our study is the largest to describe plasma sRAGE values in CFp and the only one carried out in pediatric CF population.
- 11 January 2023
- Published by Wiley
Open Access“Soluble form of the receptor for advanced glycation end products (sRAGE) as a marker of inflammation in pediatric cystic fibrosis population, a pilot study.”
The receptor for advanced glycation end products (RAGE) has been studied in several respiratory diseases described as an important inflammatory mediator. The RAGE-axis is activated by multiple endogenous ligands related to pro-inflammatory states, upregulate the RAGE expression. The function of soluble RAGE (sRAGE) is not completely understood, it has been hypothesized an anti-inflamatory role as RAGE decoy receptor. Few studies have explored the RAGE-axis in Cystic Fibrosis (CF) with contradictory results. Based on previously, we present this pilot study with the aim of describe the plasma sRAGE levels in children with cystic CF (CFp), compare with the sRAGE levels in a healthy cohort and study its possible correlation with CFp clinical features. We conducted a single-center, cross-sectional observational study. We included 35 clinically stable CF patients (aged < 18 years). The median plasma sRAGE level in CFp was 1494,75 pg/ml [interquartile range (IQR) 708,75pg/ml], compared with 714,20 pg/ml (IQR 490,50 pg/ml)) in the historical cohort of healthy controls (p < 0,001). A positive correlation was found between plasma sRAGE level and forced expiratory volume in 1 second/forced vital capacity ratio (FEV1/FVC) (p 0,004) and forced expiratory flow between 25% and 75% (FEF25%-75%) (p 0,032). In this preliminary study, the plasma sRAGE level were higher in CFp than in healthy controls. Also, we described a positive correlation between FEV1/FVC and FEF25%-75% and plasma sRAGE. To our knowledge, our study is the largest to describe plasma sRAGE values in CFp and the only one carried out in pediatric CF population.
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 980-991
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 980-991
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.